Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciaf635
- PMID
- 41253696
- PMCID
- PMC13075511
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
These quantitative projections help guide institutional planning for post-viral eradication monitoring programs, especially as therapeutic access widens across different regions.
Structured evidence summary
Research question
What is the incidence of hepatocellular carcinoma following successful antiviral therapy for hepatitis C among individuals coinfected with HIV and existing advanced liver disease?
Study design
A retrospective cohort investigation pooling participant data from multiple international research networks spanning Europe and North America.
Population and setting
Adults harboring both HIV and hepatitis C infections who presented with significant hepatic scarring or cirrhosis and lacked prior exposure to direct-acting antiviral medications.
Main findings
Approximately two and a half percent of treated participants received a hepatocellular carcinoma diagnosis within six years. Yearly occurrence rates steadily diminished, eventually dropping below zero point four percent after the third year of follow-up.
Public-health relevance
These quantitative projections help guide institutional planning for post-viral eradication monitoring programs, especially as therapeutic access widens across different regions.
Important limitations
The investigation utilizes observational registry data rather than controlled experimental frameworks, which may restrict broader applicability. Furthermore, this assessment depends exclusively on the provided abstract and bibliographic details, necessitating full manuscript review for rigorous methodological validation.
GIDS interpretation
This work contributes to scholarly discourse surrounding post-treatment oncology screening intervals, reflecting current academic focus on optimizing long-term care pathways for complex viral coinfections.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.